Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Hemophilia A Treatment Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.
Hemophilia is a condition in which the body is not able to form blood clots in order to stop bleeding. In a normal person’s body, the blood contains certain chemical substances which create a clot in case of bleeding. However, when a person has hemophilia, some clotting factors are absent which leads to the body being unable to form any clot. This result in continuous bleeding and eventually, severe loss of blood.
Hemophilia A is a rare genetic disorder of the blood characterized by a deficiency in the production of plasma protein factor VIII, which results in a reduced clotting property of the blood. Hemophilia drugs are given to hemophilic patients in order to provide them with these clotting factors artificially.
Hemophilia A Treatment Sector: Growth Drivers and Challenges
Growth Drivers
Rising Instances of Genetic Disorders to Boost the Market Growth
The cases of genetic disorders such as hemophilia have been growing significantly in the past few years and are estimated to grow further in the coming years. According to the National Hemophilia Foundation, Hemophilia A occurs in 1 out of 5,000 live male births in the United States. Additionally, hemophilia A is four times more common than hemophilia B. About 20,000 people in the United States are estimated to have hemophilia. Globally, around 400,000 people are predicted to be hemophilic. The report mentioned that approximately 75% of people with hemophilia do not receive proper treatment. On the back of these statistics, the market for hemophilia A drugs is anticipated to grow over the forecast period.
Challenges
High Cost of Treatment for Hemophilia A to Restrict the Market Growth
The high costs associated with the drugs as well as the therapies available for hemophilia A treatment is predicted to make them unaffordable for a large section of the society, specially people belonging to the low- and middle-income countries. On the basis of this factor, the hemophilia A drugs market is estimated to observe limited growth in coming years.
Hemophilia A Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
XX |
|
Base Year Market Size (2024) |
XX |
|
Forecast Year Market Size (2037) |
XX |
|
Regional Scope |
|
Hemophilia A Treatment Segmentation
The market is segmented by product, by route of administration, by distribution channel and by region, out of which, the product segment is further segmented into plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, antifibrinolytics, desmopressin and others. The segment for plasma derived coagulation factors is anticipated to hold the largest share in the hemophilia A treatment market on account of highest usage as compared with other products. Plasma derives coagulation factors further can be segmented into factors such as factor VIII, factor IX, factor XIII, von Willebrand factor and active prothrombin complex concentrates. As a result of this, the segment accounts for the highest share in the market. The segment for route of administration is further segmented into intravenous, oral, nasal and others, out of which, the intravenous segment currently holds the largest share in the market. Since the majority of hemophilia A treatment are in the form of injectable drugs, the market share of this route of administration is high. Moreover, administration of the drug directly into the blood is preferred over other routes. The segment for distribution channel is segmented into hospital pharmacy, retail pharmacy and online pharmacy. The segment for retail pharmacy is predicted to hold the leading share in the market as a result of growing preference of people for buying medicines are the pharmacies near their homes. On the other hand, the online pharmacy segment is anticipated to witness the highest growth rate on account of increasing demand of buying products online as ease of convenience of buying medications through online portals and having them delivered at home.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By Route of Administration |
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportHemophilia A Treatment Industry - Regional Synopsis
On the basis of regional analysis, the hemophilia A treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is poised to account for largest revenue share by 2037, attributed to recent advancements in the healthcare industry as well as the research and development of new drugs. Moreover, increased drug approvals further contribute towards the growth of market in this region. The market in Asia Pacific, however, is estimated to observe the highest growth rate over the forecast period as a result of rising number of patients with hemophilia A and growing awareness about the need for preventing and treating hemophilia in the region.
Companies Dominating the Hemophilia A Treatment Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd
- Novo Nordisk A/S
- Genzyme Corporation
- Grifols, S.A.
- CSL Behring
- Octapharma AG
- Aptevo Therapeutics
- Ferring Pharmaceuticals
In the News
- On April 1, 2020, the U.S. Food and Drug Administration approved Sevenfact [coagulation factor VIIa (recombinant)-jncw], a drug containing a recombinant analog of human FVII as the active ingredient, for the treatment as well as control of bleeding in people above the age of 12 with hemophilia A or B.
Author Credits: Radhika Pawar
- Report ID: 2422
- Published Date: Jan 06, 2025
- Report Format: PDF, PPT
